Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions

Neurology

Volumn 80, Issue 17, 2013, Pages 1557-1564

  Burns, Christine M ^a,e   Chen, Kewei ^c,e   Kaszniak, Alfred W ^a,b,e   Lee, Wendy ^c,e   Alexander, Gene E ^a,b,e   Bandy, Daniel ^c,e   Fleisher, Adam S ^c,e   Caselli, Richard J ^d,e   Reiman, Eric M ^b,c,e  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e ARIZONA ALZHEIMER S CONSORTIUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; ALGORITHM; ALZHEIMER DISEASE; ARTICLE; BRAIN MAPPING; BRAIN REGION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; AGED; BRAIN; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BLOOD GLUCOSE; BRAIN; BRAIN MAPPING; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

MLCS; MLOWN;

EID: 84878918038     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31828f17de     Document Type: Article

References (26)

1. Luchsinger JA. Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis 2012;30:S185-S198.
2. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 2009;66:300-305.
3. Yaffe K. Metabolic syndrome and cognitive disorders: is the sum greater than its parts? Alzheimer Dis Assoc Disord 2007;21:167-171.
4. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004;63:658-663.
5. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 2007;56:211-216.
6. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002;159:738-745.
7. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127.
8. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334;752-758.
9. Reiman EM, Chen K, Alexander GE, et al. Correlations between apolipoprotein E e4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci USA 2005;102:8299-8302.
10. Reiman EM, Chen K, Langbaum JB, et al. Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. Neuroimage 2010;49:169-176.
11. Langbaum JB, Chen K, Launer LJ, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging 2012;33:827. e11-827. e19.
12. Reiman EM, Langbaum JB, Fleisher AS, et al. Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26:321-329.
13. Waxman AD, Herholz K, Lewis DH, et al. Society of Nuclear Medicine procedure guideline for FDG PET brain imaging [online]. Available at: http://interactive.snm.org/index.cfm?PageID=8490. Accessed July 10, 2010.
14. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. New York: Thieme; 1998.
15. Reiman EM, Lane RD, Ahern GL, et al. Neuroanatomical correlates of externally and internally generated human emotion. Am J Psychiatry 1997;154:918-925.
16. Caselli RJ. Age-related memory decline and apolipoprotein E e4. Discov Med 2009;8:47-50.
17. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011;68:51-57.
18. Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med 1995;36:1141-1149.
19. Cherbuin N, Sachdev P, Anstey KJ. Higher normal fasting plasma glucose is associated with hippocampal atrophy: the PATH study. Neurology 2012;79:1019-1026.
20. Tan ZS, Beiser AS, Fox CS, et al. Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham Offspring Study. Diabetes Care 2011;34:1766-1770.
21. Rasgon NL, Kenna HA, Wroolie TE, et al. Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease. Neurobiol Aging 2011;32:1942-1948.
22. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-645.
23. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38.
24. Kawasaki K, Ishii K, Saito Y, Oda K, Kimura Y, Ishiwata K. Influence of mild hyperglycemia on cerebral FDG distribution patterns calculated by statistical parametric mapping. Ann Nucl Med 2008;22:191-200.
25. De La Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012;72:49-66.
26. Panza F, Frisardi V, Capurso C, et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis 2010;21:691-724.